Halozyme Therapeutics, Inc. (HALO)
Valor JustoFundamental
70
Preço
$108.56
Capitalização de Mercado
$12.53B
Parte 1 · Quanto vale a empresa
Visão Geral
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 de setembro de 2026 with claude-haiku-4-5 — shared with all users
West sells self-injection systems such as the SmartDose wearable injector to the same biopharma customers looking to move an infused drug into a patient-administered subcutaneous format.
Alteogen's ALT-B4 hyaluronidase is the only validated alternative to Halozyme's rHuPH20 for converting intravenous biologics to subcutaneous injection, and it has taken licensing deals with Merck, AstraZeneca and Novartis that Halozyme was competing for.
Enable's enFuse on-body injector lets pharmaceutical companies move large-volume intravenous drugs to subcutaneous administration without a hyaluronidase, chasing the same partnerships and the same royalty streams as Halozyme.
Ypsomed supplies pharmaceutical companies with autoinjector and pen platforms for self-administered biologics, the same device business Halozyme bought with Antares Pharma.
SHL Medical designs and manufactures autoinjectors for large pharmaceutical partners, competing directly for the device-development and manufacturing contracts that feed Halozyme's specialty product line.
Amphastar's Amphadase is the bovine hyaluronidase that Halozyme's own 10-K names as the competing product to its marketed drug Hylenex.
Balanço & Liquidez
Receita
$1.66B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$414M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$645M
Capital Próprio Total
$49M
Passivo Total
$2.48B
Rácio de Liquidez
2.71
Cobertura de Juros
29.41
Dívida/EBITDA
4.53
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$141.68
Preço Atual
$108.56
Margem de Segurança
+23.4%
Intervalo de Valor Justo
$92.09 - $191.27
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
32.28
ROE
649.2%
Rácio P/B
87.29
P/FCF
15.54
Margem Bruta
82.4%
ROIC
21.1%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
21.1%
WACC
8.4%
ROIC − WACC
+12.7 pp
O ROIC supera o custo do capital — a empresa está a criar valor para os acionistas.
Critérios de Análise Fundamental
Aprovado (19)
- EPS shows upward trend
- Price CAGR 27.54%
- ROIC 21.1%
- Gross Margin 82.4%
- P/FCF 15.54
- Operating Margin 35.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 180.6%
- Revenue Growth 5Y 39.2%
- Analyst Consensus 81% Buy
- PEG Ratio 1.34
- Earnings Quality (OCF/NI) 1.98
- Share Dilution -4.4%
- Piotroski F-Score 5/9
Reprovado (7)
- P/B Ratio 87.29
- Debt/Equity ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg -20.7%
- Net Margin Trend 24.9% vs 47.3%
Indisponível (1)
- Dividend Payout NaN%
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, CEO & Director | 62 |
| Mr. Mark Snyder Esq. | Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 58 |
| Mr. Darren Snellgrove | Senior VP & CFO | - |
| Mr. Brian Sweeney | Chief Human Resources Officer | 61 |
| Mr. David A. Ramsay MBA | President of Drug Delivery | 60 |
| Dr. Christopher Wahl M.B.A., M.D. | Chief Scientific Officer | - |
| Dr. Charles P. Theuer M.D., Ph.D. | Chief Medical Officer | 61 |
| Mr. Paul Spence | Chief Commercial Officer | 56 |
| Mr. Rhys de Callier | Chief Strategy Officer | - |
| Mr. Chase Coffman Ph.D. | President of Hypercon | - |
Risco de Auditoria
3
Risco do Conselho
1
Risco de Remuneração
4
Risco dos Direitos dos Acionistas
3
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2026-02-17
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-06
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-09-30
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for HALO, sourced from Markets Gazette.